Heart transplantation in cardiac amyloidosis

Matthew Sousa, Gregory Monohan, Navin Rajagopalan, Alla Grigorian, Maya Guglin

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations


“Cardiac amyloidosis” is the term commonly used to reflect the deposition of abnormal protein amyloid in the heart. This process can result from several different forms, most commonly from light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis, which in turn can represent wild-type (ATTRwt) or genetic form. Regardless of the origin, cardiac involvement is usually associated with poor prognosis, especially in AL amyloidosis. Although several treatment options, including chemotherapy, exist for different forms of the disease, cardiac transplantation is increasingly considered. However, high mortality on the transplantation list, typical for patients with amyloidosis, and suboptimal post-transplant outcomes are major issues. We are reviewing the literature and summarizing pros and cons of listing patients with amyloidosis for cardiac or combine organ transplant, appropriate work-up, and intermediate and long-term outcomes. Both AL and ATTR amyloidosis are included in this review.

Original languageEnglish
Pages (from-to)317-327
Number of pages11
JournalHeart Failure Reviews
Issue number3
StatePublished - May 1 2017

Bibliographical note

Publisher Copyright:
© 2017, Springer Science+Business Media New York.


  • Cardiac amyloidosis
  • Heart failure
  • Heart transplantation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Heart transplantation in cardiac amyloidosis'. Together they form a unique fingerprint.

Cite this